Avenue Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Note 1 - Organization, Plan of Business Operations (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Sep. 30, 2024	May 10, 2024	Jan. 09, 2024	Dec. 31, 2023
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized (in shares)	200,000,000		200,000,000	75,000,000
Retained Earnings (Accumulated Deficit)	$ (101,036)			$ (90,928)

Amount of accumulated undistributed earnings (deficit).